Evidence map›Paper›PMID 36209221›Full record

ArticleJournal of translational medicine2022

Record linkage based patient intersection cardinality for rare disease studies using Mainzelliste and secure multi-party computation.

Tobias Kussel, Torben Brenner, Galina Tremper, Josef Schepers, Martin Lablans, Kay Hamacher

Abstract read
In one paragraph

Article in Journal of translational medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Clinical Research Informatics: Contributions from 2022.Yearbook of medical informatics · 2023
    Trial
  2. Article
  3. Article
  4. [Improving record linkage for health research-how to overcome deficiencies?]Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz · 2025
    Article
  5. Article
  6. Article
  7. SPIKE: secure and private investigation of the kidney exchange problem.BMC medical informatics and decision making · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Tobias KusselTechnische Universität Darmstadt, Schnittspahnstraße 10, 64287, Darmstadt, Germany. kussel@bio.tu-darmstadt.de.ORCID 0000-0002-9731-7666
Torben BrennerGerman Cancer Research Center, Im Neuenheimer Feld 580, 69120, Heidelberg, Germany.
Galina TremperGerman Cancer Research Center, Im Neuenheimer Feld 580, 69120, Heidelberg, Germany.
Josef SchepersBerlin Institute of Health, Anna-Louisa-Karsch-Str. 2, 10178, Berlin, Germany.
Martin Lablans *German Cancer Research Center, Im Neuenheimer Feld 580, 69120, Heidelberg, Germany.
Kay Hamacher *Technische Universität Darmstadt, Schnittspahnstraße 10, 64287, Darmstadt, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe low number of patients suffering from any given rare diseases poses a difficult problem for medical research: With the exception of some specialized biobanks and disease registries, potential study participants' information are disjoint and distributed over many medical institutions. Whenever some of those facilities are in close proximity, a significant overlap of patients can reasonably be expected, further complicating statistical study feasibility assessments and data gathering. Due to the sensitive nature of medical records and identifying data, data transfer and joint computations are often forbidden by law or associated with prohibitive amounts of effort. To alleviate this problem and to support rare disease research, we developed the Mainzelliste Secure EpiLinker (MainSEL) record linkage framework, a secure Multi-Party Computation based application using trusted-third-party-less cryptographic protocols to perform privacy-preserving record linkage with high security guarantees. In this work, we extend MainSEL to allow the record linkage based calculation of the number of common patients between institutions. This allows privacy-preserving statistical feasibility estimations for further analyses and data consolidation. Additionally, we created easy to deploy software packages using microservice containerization and continuous deployment/continuous integration. We performed tests with medical researchers using MainSEL in real-world medical IT environments, using synthetic patient data.

resultsWe show that MainSEL achieves practical runtimes, performing 10 000 comparisons in approximately 5 minutes. Our approach proved to be feasible in a wide range of network settings and use cases. The "lessons learned" from the real-world testing show the need to explicitly support and document the usage and deployment for both analysis pipeline integration and researcher driven ad-hoc analysis use cases, thus clarifying the wide applicability of our software. MainSEL is freely available under: https://github.com/medicalinformatics/MainSEL

conclusionsMainSEL performs well in real-world settings and is a useful tool not only for rare disease research, but medical research in general. It achieves practical runtimes, improved security guarantees compared to existing solutions, and is simple to deploy in strict clinical IT environments. Based on the "lessons learned" from the real-word testing, we hope to enable a wide range of medical researchers to meet their needs and requirements using modern privacy-preserving technologies.

Indexed as

Biomedical ResearchComputer SecurityHumansPrivacyRare DiseasesSoftwareIntersection cardinalityMedical informaticsMulti-party computationRare diseaseRecord linkage

Identifiers

PMID36209221
PMCPMC9547637

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.